Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2022 | An overview of the RADAR trial

Karthik Ramasamy • 3 Apr 2022
BSH 2022
Multiple Myeloma
RADAR

Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, gives an overview of the actively-recruiting RADAR trial (ISRCTN46841867; UK-MRA Myeloma XV), which aims to give newly diagnosed, transplant eligible myeloma patients access to novel therapies. Dr Ramasamy briefly explains the main aims of the RADAR trial and the number of patients that have been recruited, as well as the excitement surrounding this trial and the future treatment of multiple myeloma. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.

More from Karthik Ramasamy

1:17
Novel agents to improve outcomes for patients with multiple myeloma in the salvage setting
Karthik Ramasamy • 20 Dec 2023
2:42
Optimizing maintenance therapy in multiple myeloma: an analysis from the PREAMBLE registry
Karthik Ramasamy • 20 Dec 2023
2:05
RADAR: guiding treatment for NDMM with MRD and genetic risk
Karthik Ramasamy • 20 Dec 2023
2:25
OxCOM: monitoring monoclonal gammopathies for progression to active myeloma
Karthik Ramasamy • 20 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals